Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Gains Imaging Agent Pipeline Via DuPont Pharmaceuticals Acquisition

This article was originally published in The Gray Sheet

Executive Summary

Bristol-Myers Squibb's acquisition of DuPont Pharmaceuticals includes an R&D pipeline of two imaging agents, one of which is pending at FDA, and a radiotherapeutic.

You may also be interested in...



Cardiolite MI Imaging Test Data May Prompt SPECT Practice Guideline

An emergency screening protocol for myocardial ischemia with single-photon emission computed tomography (SPECT) may be included in AHA/ACC practice guidelines as early as next year

Cardiolite MI Imaging Test Data May Prompt SPECT Practice Guideline

An emergency screening protocol for myocardial ischemia with single-photon emission computed tomography (SPECT) may be included in AHA/ACC practice guidelines as early as next year

DuPont Pictures Definity Imaging Agent Launch Supported By User Training

DuPont Pharmaceuticals plans to support an autumn launch of its Definity echocardiography ultrasound contrast agent with a user training program.

Related Content

UsernamePublicRestriction

Register

MT015011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel